Entera Bio Ltd

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Entera Bio Ltd. (ENTX) Interim CEO Roger Garceau on Q2 2020 Results - Earnings Call Transcript

‒ 6-Month Interim Data Indicate  EB 613 Has Meaningful and Positive Impact on  Lumbar Spine  Bone Mineral Density (BMD) in a Dose  Dependent Manner –  ‒ Company Expects to Complete Patient Enrollment in Q3:20 and Report Interim  Biomarker Data from 2.5 mg Dose in Q1:21 with Final Data Expected in Q2:21  ‒  ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒

Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results

BOSTON and JERUSALEM, Aug.  17, 2020  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2020 on August 20, 2020, before the U.S. financial markets open. 

Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020

BOSTON and JERUSALEM, Aug.  10, 2020  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Roger Garceau as Interim Chief Executive Officer, effective immediately.  Dr. Garceau will succeed Chief Executive Officer and Board Member Adam Gridley, who has resigned from the company to pursue a new opportunity.  Dr. Garceau will continue to serve as a Director of Entera Bio. 

Entera Bio Announces Management Changes

BOSTON and JERUSALEM, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:30 p.m. EDT. 

Entera Bio to Present at BTIG’s Virtual Biotechnology Conference

‒  Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis  ‒

Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results

‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒

Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis

Entera Bio Ltd.'s (ENTX) CEO Adam Gridley on Q1 2020 Results - Earnings Call Transcript

‒ Statistically Significant One Month Increases in P1NP Biomarker   from First 50% of Patients with Highest Dose of EB613 ‒  ‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six Months   for Bone Mineral Density Data and Evaluate Additional Higher Doses of EB613 ‒  ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒

Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q4 2019 Results - Earnings Call Transcript

BOSTON and JERUSALEM, Dec.  18, 2019  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced private placement offering (the “Offering”) with a select group of accredited investors (the “Purchasers”), bringing the anticipated aggregate gross proceeds to $14.3 million from the sale of an aggregate of 6,047,693 ordinary shares, par value NIS 0.0000769 per share (the “Shares”) at a price of $2.37 per share. In addition, as part of the offering, the Company has granted the Purchasers and certain finders an aggregate of 3,300,637 three-year warrants to purchase up to an additional 3,300,637 ordinary shares at an exercise price between $2.37 and $2.96 per share (the “Warrants” and together with the Shares, the “Securities”).

Entera Bio Announces the Completion of $14.3 million Private Placement

BOSTON and JERUSALEM, Dec.  11, 2019  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed a private placement offering  (the “Offering”) with a select group of accredited investors, including certain board members or their affiliates (the “Purchasers”), under which it received gross proceeds of $11.8 million from the sale of 4,982,301 ordinary shares, par value NIS 0.0000769 per share at a price of $2.37 per share (the “Shares”). In addition, the Company has granted the Purchasers and certain finders an aggregate of 2,693,573 three-year warrants to purchase up to an additional 2,693,573 ordinary shares at an exercise price between $2.37 and $2.96 per share (the “Warrants” and together with the Shares, the “Securities”).

Entera Announces Closing of Private Placement

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q3 2019 Results - Earnings Call Transcript

BOSTON and JERUSALEM, Nov.  21, 2019  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the Company’s future financing efforts to support the company’s growth initiatives.

Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

BOSTON and JERUSALEM, Nov.  21, 2019  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.

Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update

JERUSALEM and BOSTON, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug [Oral hPTH(1-34)].  The results were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Orlando, Florida on September 22, 2019.

Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q2 2019 Results - Earnings Call Transcript

JERUSALEM and BOSTON, Aug.  20, 2019  (GLOBE NEWSWIRE) --  Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for second quarter ended June 30, 2019.

Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update

Entera Bio Ltd. (ENTX) CEO Phillip Schwartz on Q4 2018 Results - Earnings Call Transcript

News for Entera Bio Ltd Stock (ENTX)